April 24, 2024Open Access

Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Key Points

Key points are not available for this paper at this time.

Abstract

Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Hanna et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e6dc18b6db643587657f34 — DOI: https://doi.org/10.1038/s41416-024-02685-9

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer· 2018 · 4,320 citations
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs· 2018 · 93 citations
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort· 2018 · 278 citations
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy

Authors

Daire Hanna

Sophie Merrick

Aruni Ghose

Journals

British Journal of Cancer

Actions

Institutions

Guy's and St Thomas' NHS Foundation Trust

Royal Marsden NHS Foundation Trust

Chelsea and Westminster Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion